

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司\*)

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 897)

### INSIDE INFORMATION AND PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2016, the Group expects to record a loss attributable to owners of the parent for the six months ended 30 September 2016 as compared to the profit attributable to owners of the parent in the corresponding period in 2015.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司\*) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders and potential investors of the Company that the Group expects to record a loss attributable to owners of the parent for the six months ended 30 September 2016 (“**2016**”) as compared to the profit attributable to owners of the parent in the corresponding period in 2015 (“**2015**”). The primary reasons for the expected deterioration of results performance, among other things, are: (1) a loss in fair value of equity investments at fair value through profit or loss (net) is recorded in 2016 whereas a gain in fair value of equity investments at fair value (net) was recorded in 2015; and (2) a share of losses in associates is expected to be recorded for 2016 whereas a share of profit in an associate was recorded in 2015; which were offset by the effect that a loss on deemed partial disposal of equity interests in an associate was accounted for in 2015 whereas there is no such loss in 2016 and a gain on disposal of a property is realised in 2016.

\*For identification purpose only

As the Company is still in the course of finalising its interim results for the six months ended 30 September 2016, the information contained in this announcement is only based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2016 which has yet to be finalised. Details of the performance of the Company will be disclosed in the interim results announcement which is expected to be released in November 2016.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
(位元堂藥業控股有限公司\*)  
**Chan Chun Hong, Thomas**  
*Managing Director*

Hong Kong, 12 October 2016

*As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas and Ms. Tang Mui Fun and the independent non-executive directors of the Company are Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.*

\* For identification purpose only